The Centers for Medicare & Medicaid Services Friday issued a national decision to cover diagnostic laboratory tests using next generation sequencing for certain Medicare patients with advanced cancer. “These tests can help doctors consult with patients about more targeted care or enrollment in a clinical trial,” said CMS Chief Medical Officer Kate Goodrich, M.D. “The expanded coverage in this final [national coverage determination] now includes additional tests for relapsed, refractory and earlier stage III cancers to aid in the treatment of these cancer patients.”

Related News Articles

Headline
Twelve organizations, including the AHA, Friday urged the Centers for Medicare…
Headline
The Medicare Payment Advisory Commission this week recommended that Congress provide a 2 percent market-basket update for the hospital inpatient an
Headline
The Center for Medicare and Medicaid Innovation today announced a new
Headline
Commenting today on the Medicare Payment Advisory Commission’s draft recommendations for 2020, AHA said it supports the recommendation to provide current law…
Headline
The U.S. Supreme Court yesterday heard oral arguments in an appeal of a D.C. Circuit Court decision that the Department of Health and Human Services violated…
Headline
The Centers for Medicare…